472 related articles for article (PubMed ID: 10399897)
1. Individualizing therapy to prevent long-term consequences of estrogen deficiency in postmenopausal women.
Col NF; Pauker SG; Goldberg RJ; Eckman MH; Orr RK; Ross EM; Wong JB
Arch Intern Med; 1999 Jul; 159(13):1458-66. PubMed ID: 10399897
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of raloxifene and hormone replacement therapy in postmenopausal women: impact of breast cancer risk.
Armstrong K; Chen TM; Albert D; Randall TC; Schwartz JS
Obstet Gynecol; 2001 Dec; 98(6):996-1003. PubMed ID: 11755544
[TBL] [Abstract][Full Text] [Related]
3. Modeling the annual costs of postmenopausal prevention therapy: raloxifene, alendronate, or estrogen-progestin therapy.
Mullins CD; Ohsfeldt RL
J Manag Care Pharm; 2003; 9(2):150-8. PubMed ID: 14613344
[TBL] [Abstract][Full Text] [Related]
4. [Hormone replacement and selective estrogen receptor modulators (SERMS) in the prevention and treatment of postmenopausal osteoporosis].
Pfeilschifter J
Orthopade; 2001 Jul; 30(7):462-72. PubMed ID: 11515185
[TBL] [Abstract][Full Text] [Related]
5. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women.
Walsh BW; Kuller LH; Wild RA; Paul S; Farmer M; Lawrence JB; Shah AS; Anderson PW
JAMA; 1998 May; 279(18):1445-51. PubMed ID: 9600478
[TBL] [Abstract][Full Text] [Related]
6. [Effects of estrogen and selective estrogen receptor modulators on osteoporosis].
Urano T
Clin Calcium; 2005 Apr; 15(4):591-5. PubMed ID: 15802770
[TBL] [Abstract][Full Text] [Related]
7. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
[TBL] [Abstract][Full Text] [Related]
8. [Which is the better choice, estrogen or SERMs in postmenopausal women?].
Shintani M
Clin Calcium; 2004 Oct; 14(10):105-10. PubMed ID: 15577140
[TBL] [Abstract][Full Text] [Related]
9. Prevention and treatment of osteoporosis in women with breast cancer.
Mincey BA; Moraghan TJ; Perez EA
Mayo Clin Proc; 2000 Aug; 75(8):821-9. PubMed ID: 10943237
[TBL] [Abstract][Full Text] [Related]
10. Hormone replacement therapy, selective estrogen receptor modulators, and tissue-specific compounds: cardiovascular effects and clinical implications.
Vogelvang TE; van der Mooren MJ; Mijatovic V
Treat Endocrinol; 2004; 3(2):105-15. PubMed ID: 15743106
[TBL] [Abstract][Full Text] [Related]
11. Clinical effects of raloxifene hydrochloride in women.
Khovidhunkit W; Shoback DM
Ann Intern Med; 1999 Mar; 130(5):431-9. PubMed ID: 10068418
[TBL] [Abstract][Full Text] [Related]
12. Validation of a decision model for preventive pharmacological strategies in postmenopausal women.
Perreault S; Levinton C; Laurier C; Moride Y; Ste-Marie LG; Crott R
Eur J Epidemiol; 2005; 20(1):89-101. PubMed ID: 15756909
[TBL] [Abstract][Full Text] [Related]
13. The impact of risk on preference values: implications for evaluations of postmenopausal osteoporosis therapy.
Coyle D; Wells G; Graham I; Lee KM; Peterson JE; Papadimitropoulos E
Value Health; 2001; 4(5):385-91. PubMed ID: 11705129
[TBL] [Abstract][Full Text] [Related]
14. Hormone and nonhormone therapy for the maintenance of postmenopausal health: the need for randomized controlled trials of estrogen and raloxifene.
Barrett-Connor E; Wenger NK; Grady D; Mosca L; Collins P; Kornitzer M; Cox DA; Moscarelli E; Anderson PW
J Womens Health; 1998 Sep; 7(7):839-47. PubMed ID: 9785310
[TBL] [Abstract][Full Text] [Related]
15. Raloxifene: a review of its use in postmenopausal osteoporosis.
Clemett D; Spencer CM
Drugs; 2000 Aug; 60(2):379-411. PubMed ID: 10983739
[TBL] [Abstract][Full Text] [Related]
16. Hormone replacement therapy: II. A pharmacoeconomic appraisal of its role in the prevention of postmenopausal osteoporosis and ischaemic heart disease.
Whittington R; Faulds D
Pharmacoeconomics; 1994 Jun; 5(6):513-54. PubMed ID: 10147266
[TBL] [Abstract][Full Text] [Related]
17. Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women.
Lee WL; Chao HT; Cheng MH; Wang PH
Maturitas; 2008 Jun; 60(2):92-107. PubMed ID: 18534794
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of alternative treatments for women with osteoporosis in Canada.
Goeree R; Blackhouse G; Adachi J
Curr Med Res Opin; 2006 Jul; 22(7):1425-36. PubMed ID: 16834841
[TBL] [Abstract][Full Text] [Related]
19. Patient-specific decisions about hormone replacement therapy in postmenopausal women.
Col NF; Eckman MH; Karas RH; Pauker SG; Goldberg RJ; Ross EM; Orr RK; Wong JB
JAMA; 1997 Apr; 277(14):1140-7. PubMed ID: 9087469
[TBL] [Abstract][Full Text] [Related]
20. [Indications for hormone replacement therapy].
Birkhäuser MH
Ther Umsch; 2000 Oct; 57(10):635-42. PubMed ID: 11081375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
